# Ocrelizumab in Breastmilk

> **NCT04387110** · — · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 30 (actual)

## Conditions studied

- Multiple Sclerosis
- Clinically Isolated Syndrome

## Interventions

- **DRUG:** Ocrelizumab

## Key facts

- **NCT ID:** NCT04387110
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-07
- **Primary completion:** 2022-03-01
- **Final completion:** 2022-03-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04387110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04387110, "Ocrelizumab in Breastmilk". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04387110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*